PTIX
Protagenic Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.95
−5.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 32.4K | 37.7K | 50.3K | 28.2K | 30.00 |
| Gross Profit | (32.4K) | (37.7K) | (50.3K) | (28.2K) | (30.00) |
| Operating Expenses | |||||
| R&D Expense | 617.7K | 1.7M | 3.8M | 3.3M | 1.6M |
| SG&A Expense | 1.6M | 1.7M | 1.8M | 1.2M | 2.0M |
| General & Admin Expense | 412.7K | 1.7M | 1.8M | 1.2M | 2.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 2.0M | 2.4M | 97.0K | — | — |
| Total Operating Expenses | 4.2M | 5.8M | 5.7M | 4.5M | 3.6M |
| Cost and Expenses | 4.3M | 4.9M | 5.7M | 4.5M | 3.6M |
| Operating Income (EBIT) | (4.3M) | (5.8M) | (5.7M) | (4.5M) | (3.6M) |
| Non-Operating | |||||
| Interest Income | 58.2K | 8.1K | 43.5K | 264.5K | 185.8K |
| Interest Expense | 1.4M | 296.9K | — | 107.7K | 137.5K |
| Net Interest Income | (1.3M) | (196.3K) | 43.5K | 156.8K | 48.3K |
| Other Non-Op Income/Expense | 9.7M | 675.2K | 175.6K | (474.0K) | 2.3K |
| Non-Operating Income (excl Interest) | (244.4K) | 2.2M | (175.6K) | 365.8K | (139.7K) |
| EBT (Pre-Tax Income) | 5.5M | (5.2M) | (5.5M) | (5.0M) | (3.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | 5.5M | (5.2M) | (5.5M) | (5.0M) | (3.6M) |
| Earnings from Cont. Ops | 5.5M | (5.2M) | (5.5M) | (5.0M) | (3.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 5.5M | (5.2M) | (5.5M) | (5.0M) | (3.6M) |
| Per Share | |||||
| Basic EPS | $2.95 | ($3.45) | ($1.13) | ($1.15) | ($0.82) |
| Diluted EPS | $2.95 | ($3.45) | ($1.13) | ($1.15) | ($0.82) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 1.8M | 1.9M | 4.9M | 4.3M | 4.3M |
| Diluted Shares Outstanding | 1.8M | 1.9M | 4.9M | 4.3M | 4.3M |
| Profitability Metrics | |||||
| EBITDA | (4.0M) | (8.0M) | (5.5M) | (4.5M) | (3.4M) |
| D&A | 45.0K | 37.7K | 50.3K | 28.2K | 30.00 |
| EBIT | (4.0M) | (7.1M) | (5.5M) | (4.5M) | (3.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026